The purpose of this study is to determine the safety, tolerability, and effectiveness of the
amino acid L-isoleucine in the treatment of hot flashes in postmenopausal women.
Hot flashes affect approximately 75% of postmenopausal women. Although hormone replacement
therapy (HRT) is highly effective in reducing hot flashes, long-term HRT is associated with
increased rates of breast cancer and heart disease. Safe, effective, and well-tolerated hot
flash therapies are needed. The amino acids L-methionine and L-isoleucine have produced
reductions in hot flash frequency. However, long-term L-methionine therapy may increase
cardiovascular risks. This study will evaluate the short-term effects of L-isoleucine
therapy. Data from this study will be used to conduct long-term studies in the future.
Participants in this study will be randomly assigned to receive one of two different
L-isoleucine doses for 2 weeks. Clinic visits will be made at baseline, Week 1, and Week 10.
Participants will record the frequency and severity of their hot flashes in a diary.
- Experience over 5 hot flashes per day
- Hormone Replacement Therapy (HRT) in the past 2 months